- PaxMedica’s total gross proceeds from the offering, before deducting the placement agent’s fees and other offering expenses, were approximately $7 million
- The company intends to use the proceeds to pay an outstanding promissory note, advance development programs, and general corporate purposes
- PaxMedica received constructive feedback from its type-B meeting with the FDA, which will aid in completing the remaining paperwork necessary to file a New Drug Application
- The company is currently working on commercial lots of PAX-101, which are expected during the first half of 2024, for the New Drug Application, which is expected to be filed during the second half of 2024
PaxMedica (NASDAQ: PXMD), a clinical-stage biopharmaceutical company focused on the development of novel anti-purinergic therapies (“APTs”) for the treatment of Autism Spectrum Disorder (“ASD”) and other serious conditions with intractable neurologic symptoms, recently reported the closing of its public offering. PaxMedica’s total gross proceeds from the offering, before deducting the placement agent’s fees and other offering expenses, were approximately $7 million. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering (https://ibn.fm/XEIiL).
The previously announced public offering is an aggregate of 5,384,615 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 5,384,615 shares of common stock at a public offering price of $1.30 per share and accompanying warrant. The warrants have an…
NOTE TO INVESTORS: The latest news and updates relating to PXMD are available in the company’s newsroom at https://ibn.fm/PXMD
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]
BioMedWire is powered by IBN